NCT00806338View on ClinicalTrials.gov

An Ascending Multi-Dose, Tolerance and Pharmacokinetic Study in Obese or Overweight Type 2 Diabetic Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

November 30, 2008

Primary Completion Date

April 30, 2009

Study Completion Date

April 30, 2009

Conditions
Diabetes MellitusObesity
Interventions
DRUG

Trodusquemine (MSI-1436)

A single dose of Trodusquemine (MSI-1436) will be administered every 72 hours on Days 0, 3, 6, 9, 12, 15, 18 and 21. Doses are 3mg/m2 in cohort 1, 6mg/m2 in cohort 2 and 10mg/m2 in cohort 3.

DRUG

Placebo

Trial Locations (2)

33169

Cetero Research, Miami Gardens

78229

dgd Research, San Antonio

Sponsors
All Listed Sponsors
lead

Genaera Corporation

INDUSTRY

NCT00806338 - An Ascending Multi-Dose, Tolerance and Pharmacokinetic Study in Obese or Overweight Type 2 Diabetic Volunteers | Biotech Hunter | Biotech Hunter